Literature DB >> 10323594

Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry.

M D Wood1, K L Murkitt, M Ho, J M Watson, F Brown, A J Hunter, D N Middlemiss.   

Abstract

1. This study describes the pharmacological comparison of the muscarinic partial agonists sabcomeline, xanomeline and milameline at human cloned muscarinic receptor subtypes (hM1-5). 2. Radioligand binding studies at the hM1-5 muscarinic receptor subtypes were compared with functional studies using microphysiometry using carbachol as the standard full agonist. 3. In binding assays none of the compounds studied displayed preferential affinity for the M1,3,4 or M5 subtypes although carbachol was less potent at hM1 than hM3,4,5. 4. In functional studies, all of the compounds studied displayed similar levels of efficacy across the muscarinic receptors with the exception of M3, where there was a large apparent receptor reserve and the compounds behaved essentially as full agonists. 5. Sabcomeline was the most potent agonist in functional studies but also showed the lowest efficacy. In terms of potency, xanomeline showed some selectivity for M1 over M2 receptors and milameline showed some selectivity for M2 over M1 receptors. 6. These results show the value of microphysiometry in being able to compare receptor pharmacology across subtypes irrespective of the signal transduction pathway. 7. None of the partial agonists showed functional selectivity for M1 receptors, or indeed any muscarinic receptor, in the present study.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10323594      PMCID: PMC1565933          DOI: 10.1038/sj.bjp.0702463

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  15 in total

1.  Novel persistent activation of muscarinic M1 receptors by xanomeline.

Authors:  A Christopoulos; E E El-Fakahany
Journal:  Eur J Pharmacol       Date:  1997-09-03       Impact factor: 4.432

2.  Functional properties of muscarinic receptor subtypes Hm1, Hm3 and Hm5 expressed in Sf9 cells using the baculovirus expression system.

Authors:  J P Kukkonen; J Näsman; P Ojala; C Oker-Blom; K E Akerman
Journal:  J Pharmacol Exp Ther       Date:  1996-11       Impact factor: 4.030

3.  Regional differences in receptor reserve for analogs of oxotremorine in vivo: implications for development of selective muscarinic agonists.

Authors:  B Ringdahl; M Roch; D J Jenden
Journal:  J Pharmacol Exp Ther       Date:  1987-08       Impact factor: 4.030

4.  Nonlinear regression using spreadsheets.

Authors:  W P Bowen; J C Jerman
Journal:  Trends Pharmacol Sci       Date:  1995-12       Impact factor: 14.819

5.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

6.  SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors.

Authors:  J M Loudon; S M Bromidge; F Brown; M S Clark; J P Hatcher; J Hawkins; G J Riley; G Noy; B S Orlek
Journal:  J Pharmacol Exp Ther       Date:  1997-12       Impact factor: 4.030

7.  Induction of catecholamine-responsive adenylate cyclase in HeLa cells by sodium butyrate. Evidence for a more efficient stimulatory regulatory component.

Authors:  S Kassis; R C Henneberry; P H Fishman
Journal:  J Biol Chem       Date:  1984-04-25       Impact factor: 5.157

8.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

9.  Using microphysiometry to study the pharmacology of exogenously expressed m1 and m3 muscarinic receptors.

Authors:  G T Baxter; M L Young; D L Miller; J C Owicki
Journal:  Life Sci       Date:  1994       Impact factor: 5.037

10.  Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.

Authors:  H E Shannon; F P Bymaster; D O Calligaro; B Greenwood; C H Mitch; B D Sawyer; J S Ward; D T Wong; P H Olesen; M J Sheardown; M D Swedberg; P D Suzdak; P Sauerberg
Journal:  J Pharmacol Exp Ther       Date:  1994-04       Impact factor: 4.030

View more
  17 in total

1.  The utility of muscarinic agonists in the treatment of Alzheimer's disease.

Authors:  William S Messer
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

2.  Designing human m1 muscarinic receptor-targeted hydrophobic eigenmode matched peptides as functional modulators.

Authors:  Karen A Selz; Arnold J Mandell; Michael F Shlesinger; Vani Arcuragi; Michael J Owens
Journal:  Biophys J       Date:  2004-03       Impact factor: 4.033

3.  Chemical genomics: massively parallel technologies for rapid lead identification and target validation.

Authors:  Uli Hacksell; Norman Nash; Ethan S Burstein; Fabrice Piu; Glenn Croston; Mark R Brann
Journal:  Cytotechnology       Date:  2002-01       Impact factor: 2.058

Review 4.  Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits.

Authors:  Briana J Davie; Arthur Christopoulos; Peter J Scammells
Journal:  ACS Chem Neurosci       Date:  2013-05-23       Impact factor: 4.418

5.  SKF-83959 is not a highly-biased functionally selective D1 dopamine receptor ligand with activity at phospholipase C.

Authors:  Sang-Min Lee; Andrew Kant; Daniel Blake; Vishakantha Murthy; Kevin Boyd; Steven J Wyrick; Richard B Mailman
Journal:  Neuropharmacology       Date:  2014-06-12       Impact factor: 5.250

6.  Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey.

Authors:  Joshua D Vardigan; Christopher E Cannon; Vanita Puri; Mandy Dancho; AmyJo Koser; Marion Wittmann; Scott D Kuduk; John J Renger; Jason M Uslaner
Journal:  Psychopharmacology (Berl)       Date:  2014-12-10       Impact factor: 4.530

7.  Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1.

Authors:  C J Langmead; N E Austin; C L Branch; J T Brown; K A Buchanan; C H Davies; I T Forbes; V A H Fry; J J Hagan; H J Herdon; G A Jones; R Jeggo; J N C Kew; A Mazzali; R Melarange; N Patel; J Pardoe; A D Randall; C Roberts; A Roopun; K R Starr; A Teriakidis; M D Wood; M Whittington; Z Wu; J Watson
Journal:  Br J Pharmacol       Date:  2008-05-05       Impact factor: 8.739

8.  Immediate and delayed consequences of xanomeline wash-resistant binding at the M3 muscarinic receptor.

Authors:  Meredith J Noetzel; Marianne K O Grant; Esam E El-Fakahany
Journal:  Neurochem Res       Date:  2008-12-12       Impact factor: 3.996

Review 9.  Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists.

Authors:  Joseph I Friedman
Journal:  Psychopharmacology (Berl)       Date:  2004-02-19       Impact factor: 4.530

10.  Differential regulation of muscarinic M1 receptors by orthosteric and allosteric ligands.

Authors:  Christopher N Davis; Stefania Risso Bradley; Hans H Schiffer; Mikael Friberg; Kristian Koch; Bo-Ragnar Tolf; Douglas W Bonhaus; Jelveh Lameh
Journal:  BMC Pharmacol       Date:  2009-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.